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Intra class correlation coefficients between the countries were high: from 0.89 
(England vs. US) through 0.99 (Canada vs. US). ConClusions: This proof of con-
cept study indicates that computer-based choice tasks for the EQ-5D-5L in the 
general population are feasible and parameter of the choice tasks estimates are 
generally consistent and logical, and the estimated values are largely consistent 
between the 4 countries.
PP3
Can the Use of soCial Media and Mobile aPPs iMProve Patient 
Knowledge of disease and health oUtCoMes? a systeMatiC review
Abogunrin S., Martin A.
Evidera, London, UK
objeCtives: The use of interactive social media (SM) based on Web 2.0 technology, 
e.g. Twitter, Facebook, MySpace; and mobile apps, is increasing but its role in improving 
patient knowledge of their disease and its management is unclear. We conducted a 
systematic review to assess the evidence for health benefits from SM. Methods: We 
searched MEDLINE and EMBASE for relevant articles published in the last five years that 
used words synonymous with SM; patient, carer, or parents’ preferences, opinions or 
views; pharmacological interventions; and disease. We included comparative studies 
or systematic reviews on the use of any SM by patients, that measured differences in 
knowledge about disease, uptake of pharmacological interventions, or clinical outcomes 
from better management of disease. Articles were excluded if they reported only the 
use of SM by health care professionals, or if they were case studies, narrative reviews 
or expressed expert opinions. Results: We identified 3,232 unique abstracts, 24 of 
which reported the use of interactive, internet-delivered programs (n= 13), Facebook 
(n= 4), and mobile apps (n= 3) , for improving health outcomes of patients with cancer, 
or inflammatory, mental health, musculoskeletal, neurologic, ophthalmologic, or sexual 
health-related disorders. Patients receiving SM-based interventions showed improved 
knowledge of their disease, and better clinical outcomes compared with controls. Two 
additional studies reported on the use of SM aimed at increasing knowledge, and self-
efficacy in parents of children with cystic fibrosis. Overall, the studies showed that 
SM-based interventions improved knowledge of disease and clinical outcomes com-
pared with control groups. ConClusions: Surprisingly little research has been con-
ducted on the value of SM to aid and support patients. What evidence exists suggests 
that SM tools offer health benefits. fFrther work is needed to confirm these effects and to 
assess how best the tools might increase patients’ knowledge about disease, treatment 
adherence and clinical outcomes.
PP4
the iMPortanCe of Patient rePorted oUtCoMes in reiMbUrseMent of 
orPhan ProdUCts in eUroPe
Lyons E.J.1, McGeagh J.1, Es-Skali I.J.2, Parmenter L.3, Nijhuis T.4, Boucher G.1
1Quintiles, Reading, UK, 2Quintiles Consulting, Hoofddorp, The Netherlands, 3Quintiles Outcome, 
Reading, UK, 4Quintiles, Hoofddorp, The Netherlands
objeCtives: To determine the importance of patient reported outcomes (PROs) 
in the reimbursement of orphan drugs in Europe and identify any HTA authority 
preferences for particular PRO measures. Methods: All 31 products assigned an 
orphan designation by the European Medicines Agency (EMA), between January 
2009 and May 2013, were evaluated against the following criteria: approval for 
marketing, submission for reimbursement/price negotiation to NICE, SMC, G-BA, 
and HAS, presence or absence of PROs, approval or rejection of reimbursement 
application. Where available, HTA guidance documents resulting from the appli-
cations were reviewed in detail to determine the impact of PRO measures on the 
reimbursement decision. Results: Of the 31 products assigned an orphan des-
ignation, 26 were granted marketing authorisation by the EMA. Eleven products 
were submitted to NICE for reimbursement in England of which 7 submissions 
contained PROs and 6 were approved. In Scotland, 11 products were submitted for 
reimbursement to the SMC and of the 7 submissions containing PRO data, 3 were 
recommended for reimbursement. One submission is still pending. In Germany, 7 
products were submitted to the G-BA of which 5 contained PROs and were allowed 
to enter into price negotiations. The French HTA authority, HAS, evaluated 20 sub-
missions of which 9 contained PROs and 19 were approved. ConClusions: The 
results of our assessment of EMA approved orphan drugs indicates that a great 
deal of variation exists across Europe with respect to the evaluation of orphan 
drugs for reimbursement or price negotiation. In some countries, reimbursement is 
largely independent of evidence of reported patient benefit while in others, where 
evidence of economic value is critical for success, robust PRO data are essential.
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Cl1
a CoMParison of Methodologies for estiMating sUrvival in Patients 
treated with seCond-generation tyrosine-Kinase inhibitors (tKis) 
for ChroniC Myeloid leUKaeMia (CMl)
Pennington B.1, Batty A.J.1, Clifton-Brown E.2
1BresMed, Sheffield, UK, 2Pfizer Ltd., Tadworth, UK
objeCtives: NICE have previously recommended nilotinib, but not dasatinib, as 
a first-line (TA251) and second-line (TA241) treatment in chronic phase (CP) CML. 
Within these appraisals, different methods were used to estimate overall survival 
(OS). Bosutinib, a potent dual Src/Abl TKI, is undergoing a NICE appraisal in sec-
ond-line or later CML (ID495). The objective is to review the OS methods used and 
assess their impact on cost-effectiveness and recommendations in CML apprais-
als. Methods: We identify the methodologies used for estimating OS in TA241 
and TA251 and investigate the impact of using these to estimate OS for the TKIs, 
including bosutinib, in relapsed/refractory CML. Finally, we consider the implica-
tions of the various methodologies on the cost-effectiveness results and recom-
mendations in previous and future NICE assessments of TKIs for CML. Results: The 
base-case in TA241 used a surrogate relationship between response (MCyR) and OS 
objeCtives: Estimating transition probabilities for Markov models is challenging 
when the effectiveness of the studied intervention is measured using a continuous 
score, and only aggregate data by treatment are available. We developed a Bayesian 
calibration method to estimate transition probabilities and applied it in Parkinson’s 
disease (PD). Methods: A previously published Markov model with health states 
corresponding to Hoehn and Yahr (H&Y) stages was adapted. Patient-level datasets 
were simulated to replicate results of clinical trials for different drugs, using the 
UPDRS scale to assess severity, and transition probabilities were estimated from 
simulated data to provide a reference case. Two calibrations methods were tested for 
obtaining transition probabilities without patient-level data. Firstly, the Solver tool 
of Excel was used, with the mean change in UPDRS score and associated variance as 
targets. Secondly, a Bayesian calibration was implemented in OpenBUGS to estimate 
the posterior distribution of transition probabilities, assuming the change in UPDRS 
score has a normal distribution, with observed mean and variance. All other model 
input parameters were taken from the original model. Results: With simulated 
patient-level data, the incremental cost (IC) was estimated at € -7,015 (95% credibility 
interval: € -23,953; € 5,977) and incremental QALYs (IQ) at 0.455 (0.112; 0.950). With 
calibration using the Solver tool, there was an infinity of solutions resulting in IC 
ranging from € -10,141 to € -8,206 and IQ ranging from 0.422 to 0.473. With calibra-
tion using OpenBugs, the IC was estimated at € -6,852 (€ -24,244; € 6,448) and the 
IQ at -0.448 (0.108; 0.959). ConClusions: Incremental costs and QALYs obtained 
using the Bayesian calibration and analysis of patient-level data were similarly 
distributed. Mean results obtained using the Solver tool were comparable, but no 
statistical distribution around results could be provided. This example suggests that 
the Bayesian calibration is a valid method to derive transition probabilities from 
continuous outcome measures.
Patient PreferenCe stUdies
PP1
a Methodology for PrediCting the iMPaCt of CoPayMents on the 
Utilization of health teChnologies
Sabatelli L.
GLOB MOD, Barcelona, Spain
objeCtives: Copays (or copayments) for health-technologies, such as pharma-
ceutical products, are used by governments and insurers to prevent moral hazard, 
reduce unnecessary utilization of resources, and contribute to the cost of health 
care. Nevertheless they may also reduce access to necessary care, and the financial 
protection associated with health insurance. In addition, from the perspective of the 
manufacturer, the introduction of copays may determine unexpected and abrupt 
falls in demand. The methodology here presented uses data extracted from surveys 
on product utilization and patient income, prior and after the introduction of copays 
in various countries and regions, to predict the potential impact of copays on the 
demand for a pharmaceutical product in a given country or region. Methods: This 
approach uses multi-level multivariate regressions and a micro-economic model 
of demand (which assumes maximization of utility and preference independence) 
to anticipate changes in utilization (and therefore in demand) as a function of the 
amount of copay charges. Data from a computer simulation were used to test the 
method. Results: A non-linear relationship between copay and drug-consump-
tion, determined by the combined effect of the amount charged and of the average 
population income was identified, predicting changes in aggregate demand and in 
income-specific demand. For instance: if we consider two countries both adopting 
a 1 Euro co-pay charge on a (not easily substitutable) product and whose average 
income differs by 20%, we expect the demand to be almost 3% lower in the country 
with the lower income than in the country with the higher income. ConClusions: 
Under general market assumptions, it is possible to build models that estimate the 
potential impact of copay charges. These models can be used to help design health 
policies and market strategies.
PP2
MUltinational ConsistenCy of a disCrete ChoiCe Model in 
QUantifying health states for the extended 5-level eQ-5d
Krabbe P.F.M.1, Devlin N.J.2, Stolk E.A.3, Shah K.K.4, Oppe M.3, van Hout B.4, Quik E.H.1,  
Pickard A.S.5, Xie F.6
1University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 
2Office of Health Economics, London, UK, 3Erasmus University Rotterdam, Rotterdam, The 
Netherlands, 4University of Sheffield, Sheffield, UK, 5University of Illinois at Chicago, Chicago, IL, 
USA, 6McMaster University, Hamilton, ON, Canada
objeCtives: To investigate the feasibility of choice experiments for EQ-5D-5L 
states using computer-based data collection, and to examine the consistency of 
the estimated parameters values derived after modeling the stated preference 
data across countries in a multinational study. Methods: Similar choice experi-
ments were executed in Canada, England, The Netherlands, and United States 
(US). Interactive software was developed to standardize the format of the choice 
tasks across countries, except for England where face-to-face interviewers were 
used. The choice task required respondents to choose between two sub-optimal 
health states. A Bayesian design was used to generate 200 pairs of states that were 
randomly grouped into 20 blocks. Each respondent completed one block consisting 
of 10 pairs. A main-effect alternative-specific multinomial probit regression model 
was used to estimate regression coefficients and to derive values for each health 
state that capture the relative differences in levels between states. Results: In 
total there were 1775 respondents, at least 400 respondents from each country, 
who completed 17750 paired comparisons, resulting into 35500 assessed health 
states. The mean time to perform one choice task was between 29.2 (US) and 
45.2 (England) seconds. All regression coefficients were statistically significant, 
except level 2 for Usual Activities in The Netherlands (p= 0.51). Three regression 
coefficients with illogical ordering were observed (The Netherlands: level 3 Pain/
Discomfort, England: Level 3 Usual Activities & Pain/Discomfort). Predictions for 
the complete set of 3125 EQ-5D-5L states were similar for the four countries. 
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Evaluation (GRADE) approach using the example of male human papilloma virus 
(HPV) vaccination Europe. Methods: A pan-European multidisciplinary expert 
group was established to develop an extended GRADE framework that includes 
explicit assessment of cost-effectiveness, medical needs, and patient aspects, ethi-
cal and social issues. Using an expert panel process, we assessed the feasibility of 
using this framework by applying it to male HPV vaccination in Europe. Studies were 
assessed using the specific framework tools; results and feasibility were discussed; 
and consensus was achieved through a modified Delphi method. Results: We 
identified three advisory committees (ACIP/USA; NACI/Canada; STIKO/Germany) 
using GRADE for vaccines assessment. Institutions handled data beyond vaccine 
efficacy and safety differently and did not formally grade economic evidence. We 
adopted the grading methodology of ACIP for the key factor ‘Benefits and Harms’ 
and developed modules for grading evidence type and quality of economic evalua-
tions (‘Economic Evaluation’) and for systematically assessing epidemiology, disease 
burden and unmet medical needs, as well as ethical, social and patient aspects 
(‘Values and Preferences’). The feasibility test demonstrated that all framework 
components were feasible in the case of HPV vaccination. Overall evidence type 
for cost-effectiveness was low with uncertainty in results. Cost-effectiveness was 
best, when all HPV-related diseases and outcomes were included and when assum-
ing low coverage in females and lower vaccine prices. ConClusions: The GRADE 
approach is applicable in assessing vaccinations and was successfully applied to 
HPV vaccination in males. The assessment of benefits and harms can be extended 
by explicit assessment of the evidence on cost-effectiveness and other key fac-
tors including unmet medical needs, and ethical, social and patient aspects. This 
extended framework can better inform policy- and decison makers.
CardiovasCUlar disease oUtCoMes researCh stUdies
Cv1
Challenges in Modelling the Cost effeCtiveness of interventions in 
CardiovasCUlar disease
Burgers L.T., Redekop W.K., Severens J.L.
Erasmus University Rotterdam, Rotterdam, The Netherlands
objeCtives: Modelling is essential in performing economic evaluations for various rea-
sons. For example, modelling is necessary if extrapolation of short-term or intermediate 
results to long-term outcomes is required and numerous strategies need to be evaluated 
without direct evidence. However, modelling inherently poses challenges that need to 
be dealt with since models always represent a simplification of reality. The aim of this 
study is to identify and analyse the challenges in modelling the cost-effectiveness of 
cardiovascular disease (CVD) interventions. Methods: A questionnaire was sent to 
40 corresponding authors (systematically selected) of recent model-based economic 
evaluations of CVD interventions published in high-impact cardiovascular, health eco-
nomics and general medical journals. Respondents were asked to provide their own 
challenges and also rank the importance of challenges identified using a pilot version 
of the questionnaire distributed to 7 experienced researchers. Furthermore, we analysed 
the discussion sections of the papers to identify unmentioned challenges. Solutions, 
if available, were based on input from the respondents and the recommendations of 
the ISPOR-SMDM task force. Results: The systematic literature search identified 1720 
potentially relevant articles. The limit of 40 authors was reached after screening 294 
titles and abstracts. Beside the challenge of lack of data, preliminary results show that 
it was difficult to obtain a sufficiently valid, precise and accurate cost-effectiveness 
estimate due, for example, to interrelating clinical outcomes or extrapolating from sur-
rogate outcomes. Both challenges often exist in CEAs evaluating CVD prevention strate-
gies. ConClusions: The preliminary results of this study showed examples of CVD 
modelling challenges encountered during studies published in high-impact journals. 
Modelling guidelines do not provide sufficient assistance in resolving all challenges 
but it is probably unrealistic to expect this. Some of the reported challenges are specific 
to the type of intervention and disease, but most challenges are present in all types of 
interventions and diseases.
Cv2
aPPliCation of behavioUral eConoMiCs to the Understanding 
of adherenCe: does an individUal’s tiMe PreferenCe inflUenCe 
adherenCe to MediCations?
Fargher E.A., Morrison V., Plumpton C.O., Hughes D.A.
Bangor University, Bangor, UK
objeCtives: There is general support that individual time preference affects health-
related behaviours. People with a high, positive time preference value their imme-
diate health higher than future health, even if presented with extreme scenarios 
of intertemporal choice. We hypothesised that adherence to medication requires 
trade-offs between immediate and delayed health benefits. Patients with lower 
time preference rates may be more adherent to medication as they place a higher 
value on the future benefits of adherence. Methods: Hypertensive adult patients 
across Europe were invited to complete a web-based survey that had been translated 
and piloted. Patients’ time preference was assessed (4-items) to calculate individual 
discount rates (%) in both short term (3-years) and medium term (6-years). Medication 
adherence was measured using the Morisky questionnaire (primary analysis) and the 
Medication Adherence Report Scale (MARS, secondary analysis). Sample size calculation, 
based on 5% one-sided confidence, assuming 30% non-adherence with Morisky measure 
indicated n= 323 per country. Missing data were imputed using multiple imputation in 
STATA. The significance of the association with adherence was assessed using the Wald 
test statistic. Results: 969 patients completed the questionnaire across England, Wales 
and Hungary, 79% of possible responses were observed. Short and medium term time 
preference rates in England, Wales and Hungary were in the expected directions, but 
the relationship was not statistically significant. Based on Morisky adherence - Wales 
(short): adherent 8.7%, non-adherent 9.4% (p= 0.541); (medium): adherent 4.7%, non-
adherent 5.0% (p= 0.611). England (short): adherent 7.8%, non-adherent 9.5% (p= 0.163); 
(medium): adherent 3.7%, non-adherent 4.5% (p= 0.095). Hungary (short): adherent 
19.0%, non-adherent 18.2% (p= 0.504); (medium): adherent 8.9%, non-adherent 8.6% 
to derive OS estimates for nilotinib and dasatinib of 13.0 and 13.4 years respectively 
(second-line CP). Using the same approach for bosutinib gives an OS of 12.8 years 
(third-line CP). The base-case in TA251 used a cumulative approach, where OS is 
equal to the duration of treatments in the pathway. If this method is applied to the 
TKIs in second-line CML (TA241), OS is reduced to approximately 9.4 and 10.1 years 
for nilotinib and dasatinib respectively (second-line CP). Similarly, bosutinib OS 
(third-line CP) is also reduced using this method and a substantial increase in the 
ICER is seen. ConClusions: There are methodological inconsistencies in NICE’s 
assessments of TKIs for CML. Applying the OS methodology from TA251 to TA241 
may have led to nilotinib not being recommended for routine use in the NHS. The 
impact of new methodologies on previous appraisal results and recommendations 
should be considered when assessing the validity of a new approach.
Cl2
addressing heterogeneity in baseline risK of CoPd exaCerbations 
Using Meta-regression
Cope S.1, Buckley F.2, Baldwin M.3, Kraemer M.4, Jansen J.2
1Mapi, Toronto, ON, Canada, 2Mapi, Boston, MA, USA, 3Novartis Pharmaceuticals UK Limited, 
Horsham, West Sussex, UK, 4Novartis Pharma AG, Basel, Switzerland
objeCtives: To evaluate differences across randomized controlled trials (RCTs) con-
cerning interventions for moderate to severe chronic obstructive pulmonary disease 
(COPD) in terms of baseline exacerbation rates and the association with treatment 
effects by means of a network meta-analysis (NMA). This NMA is performed based on 
RCTs evaluating the long-acting bronchodilators indacaterol 75/150/300µg OD, salme-
terol 50µg BID, formoterol 12µg BID, tiotropium bromide 18µg/5µg OD, and glycopyr-
ronium bromide 50µg OD. Methods: The rate of moderate or severe exacerbations 
was extracted from RCTs identified with a systematic literature review. A Bayesian NMA 
was used to synthesize the treatment effects of the different trials. The association 
between treatment effects and baseline exacerbation rate with placebo was assessed 
with a meta-regression model assuming a constant treatment-by-baseline risk interac-
tion term. Results: Twenty-four RCTs were included that differed mainly in terms of 
smoking status, COPD severity, use of inhaled corticosteroids, exacerbation definition, 
and exacerbation history. Across the RCTs the rate of exacerbations per patient year for 
patients in the placebo arm ranged from 0.40 to 1.91. Baseline risk was negatively associ-
ated with the rate ratios reflecting treatment effects across the RCTs. The coefficient for 
baseline risk was -0.35 (95% credible intervals: -0.49, -0.18). ConClusions: Based on a 
NMA of RCTs regarding the efficacy of long-acting bronchodilators in terms of the rate 
of exacerbations per patient year, baseline risk of exacerbations acts as a significant 
treatment effect modifier and should be accounted for in the model.
Cl3
validation of sUrrogate endPoints in advanCed solid tUMoUrs: 
systeMatiC review of statistiCal Methods, resUlts, and 
iMPliCations for PoliCy MaKers
Ciani O.1, Davis S.2, Tappenden P.2, Garside R.3, Stein K.1, Cantrell A.2, Saad E.4, Buyse M.5, 
Taylor R.1
1University of Exeter, Exeter, UK, 2University of Sheffield, Sheffield, UK, 3University of Exeter, 
Truro, UK, 4Dendrix, Sao Paulo, Brazil, 5IDDI, Louvain-la-Neuve, Belgium
objeCtives: Licensing and reimbursement of anticancer drugs should rely on evi-
dence from patient-relevant endpoints such as overall survival (OS). Nevertheless, 
evidence from surrogate endpoints may also be useful, as it may expedite the regula-
tory approval and coverage decisions of new therapies. It is therefore essential that 
candidate surrogate endpoints be properly validated. However, there is no consensus 
on statistical methods for such validation and on how the evidence thus derived 
should be applied by policy makers. Methods: We review meta-analyses of thera-
peutic interventions against advanced solid tumours published until December 2012 
that quantified the statistical association between progression-free survival (PFS) 
or time-to-progression (TTP) and OS. We assessed the suitability of the two surro-
gates using three current surrogate validation frameworks: Bucher’s framework, the 
German Institute of Quality and Efficiency in Health Care’s (IQWiG) framework and 
the Biomarker-Surrogacy Evaluation Schema (BSES3). Results: Thirty-one meta-
analyses were included which employed a variety of statistical methods to assess 
surrogate validity. The strength of the association between PFS or TTP and OS was 
generally low. The level of evidence (observation-level vs. treatment-level) available 
supporting an association between PFS or TTP and OS varied considerably by cancer 
type, by evaluation tools and was not always consistent even within one specific 
cancer type. ConClusions: Not in all solid tumours the treatment-level associa-
tion between PFS or TTP and OS has been investigated. According to the IQWiG’s 
framework, only PFS achieved acceptable evidence of surrogacy in metastatic colo-
rectal and ovarian cancer treated with cytotoxic agents, whereas in no indication 
did the two candidate endpoints achieve good evidence of surrogacy according to 
BSES3. Our study emphasises the challenges of surrogate-endpoint validation and 
the importance of building consensus on appropriate statistical techniques to exam-
ine surrogacy and on the development of evaluation frameworks for policy makers.
Cl4
fraMeworK for evidenCe assessMent based on grade and 
aPPliCation to hPv vaCCination in Males in the eUroPean health 
Care Context
Siebert U.1, Sroczynski G.2, Baker P.3, Borget I.4, Castellsagué X.5, Chapman R.6,  
von Knebel-Doeberitz M.7, Mortensen G.L.8, La Torre G.9
1UMIT – University for Health Sciences, Medical Informatics and Technology / ONCOTYROL / Harvard 
University, Hall i. T./ Innsbruck / Boston, Austria, 2UMIT – University for Health Sciences, Medical 
Informatics and Technology, Hall i.T., Austria, 3Men’s Health Consultant, Brighton, UK, 4Institut 
Gustave Roussy, Villejuif, France, 5L’Hospitalet de Llobregat, Barcelona, Spain, 6Evidera, London, UK, 
7University of Heidelberg, German Cancer Research Center, Heidelberg, Germany, 8AnthroConsult, 
Aarhus C, Denmark, 9Sapienza University of Rome, Rome, Italy
objeCtives: To develop and apply an extended framework for evidence assess-
ment based on the Grading of Recommendations Assessment, Development and 
